Chronic Myeloid Leukemia (CML) is a clonal disease characterized by the presence of the
Philadelphia (Ph+) chromosome and its oncogenic product, BCR-ABL, a constitutively active …

Imatinib, nilotinib, and dasatinib are tyrosine kinase inhibitors (TKIs) that have become first-
line treatments for Philadelphia chromosome-positive chronic myeloid leukemia (CML) …

Although only 5000 new cases of chronic myeloid leukemia (CML) were seen in the United
States in 2009, this neoplasm continues to make scientific headlines year-after-year …

TKI discontinuation proved to be safe and feasible in patients with CML with deep and
durable molecular responses, introducing an additional treatment goal for these patients …

Purpose Dasatinib is a prototypic short half-life BCR-ABL1 tyrosine kinase inhibitor. The
recommended dose of dasatinib for chronic myeloid leukemia in chronic phase was …

Despite the outstanding results generally obtained with imatinib mesylate (IM) in the
treatment of chronic myeloid leukemia (CML), some patients show a poor molecular …

Purpose This study examined the utility of therapeutic drug monitoring (TDM) of imatinib,
nilotinib, and dasatinib in adult patients with chronic-phase chronic myeloid leukemia (CML) …

(1) Purpose: This study aimed to develop a physiologically based pharmacokinetic (PBPK)
model to predict the trough concentration (C trough) of imatinib (IMA) at steady state in …

Imatinib is the standard of care for patients with advanced metastatic gastrointestinal stromal
tumors (GIST), and is also approved for adjuvant treatment in patients at substantial risk of …

This study set out to examine in a large real‐life cohort of patients with chronic myeloid
leukemia (CML) the impact of imatinib threshold of 1000 ng/mL on molecular response, as …